DuPont research demonstrates impact of strain specificity on HMOs utilisation

Major strain specific adaptions in Bifidobacterium longum subsp. Infantis Bi-26 proves efficient utilisation of human milk oligosaccharides (HMOs), the company claimed.


Continuing its research on human milk oligosaccharides (HMOs), DuPont Nutrition & Biosciences released the findings of a new study demonstrating the importance of probiotic strain specificity, even within a sub-species, when related to efficient utilisation of HMOs.

Several species of Bifidobacterium have been shown to utilise HMOs, but minimal work has been done to study utilisation variations within the species or sub-species. This study examined two strains of B. infantis, a prevalent species in the guts of breastfed infants. DuPont reported that the study found B. infantis Bi-26 has a strategy to quickly utilise 2-Fucolsyllactose (2’-FL), 3’-FL and difucosyllactose (DFL) which results in faster growth, metabolite production, and a distinct global gene transcription response when compared to the type strain ATCC 15697.

Bryan Zabel, the study’s lead author and assistant scientist for DuPont Nutrition & Biosciences, said: “We are excited to further the research on defining the individual strain’s role within the complex system of the microbiome. It is essential to understand the numerous interactions affecting our health throughout life which can eventually be used as a guide to develop products for supplementation.”

Dr Ratna Mukherjea, technical fellow and technology and innovation leader, specialised nutrition, DuPont Nutrition & Biosciences, added: “Our research helps us to further understand the interactions between probiotic strains and HMOs, and allows us to develop targeted health products. This study marks a significant advancement in DuPont’s work in early life nutrition.”